Holen Sie sich die Stockscreener-App
26.32
5.56%
-1.55
Handel nachbörslich:
25.98
-0.34
-1.29%
Schlusskurs vom Vortag:
$27.87
Offen:
$28.48
24-Stunden-Volumen:
4.68M
Relative Volume:
1.83
Marktkapitalisierung:
$2.66B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-14.54
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+2.21%
1M Leistung:
+32.39%
6M Leistung:
+79.90%
1J Leistung:
+14.29%
1-Tages-Spanne:
$25.62
$28.62
1-Wochen-Bereich:
$24.67
$28.75
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.32 | 2.82B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus
What the charts say about Beam Therapeutics Inc. today2025 Price Targets & Community Consensus Picks - newser.com
Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Australia
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent
Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener
Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com
Technical analysis overview for Beam Therapeutics Inc. stockWatch List & Entry Point Confirmation Signals - newser.com
Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga
What Does Wall Street Think About Beam Therapeutics (BEAM)? - Yahoo Finance
Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com
Recent Insider Transactions at Beam Therapeutics - TradingView
Beam Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Beam Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating - MSN
Beam Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Budget Friendly Capital Growth - earlytimes.in
What analysts say about Beam Therapeutics Inc stockRelative Strength Index (RSI) & Master Timing Market Moves - earlytimes.in
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - MSN
H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum - MSN
Is Beam Therapeutics Inc a good long term investmentGrowth vs. Value Investing & Affordable Investment Portfolio - earlytimes.in
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Peregrine Investment Management Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Hits Day High with 7.66% Surge in Stock Price - Markets Mojo
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.2%Time to Buy? - MarketBeat
Rhumbline Advisers Has $2.76 Million Stake in Beam Therapeutics Inc. $BEAM - MarketBeat
HC Wainwright Reiterates Buy Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
How to forecast Beam Therapeutics Inc. trends using time seriesTrade Exit Summary & Low Risk High Win Rate Picks - newser.com
Beam Therapeutics Stock Soars 11.8%, Hits Intraday High of $25.12 - Markets Mojo
Beam Therapeutics (NASDAQ:BEAM) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Analysis Recap: Will Beam Therapeutics Inc benefit from geopolitical trendsTrade Ideas & Risk Controlled Daily Plans - خودرو بانک
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years - Benzinga
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):